Therefore, we can infer that the CRISPR–Cas9 system may play an important role in the recovery of LDLR mutations or defect in many other genes, including PCSK9, ApoB, and ANGPTL‐3, and would be a broadly useful therapeutic approach for FH. This evidence concerns the gene LDLR and familial hyperaldosteronism.